{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:00:02Z","timestamp":1793210402707,"version":"4.5.0"},"reference-count":96,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"unspecified","delay-in-days":296,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol Psychiatr Sci"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S2045796024000520_sec1a\">\n\t    <jats:title>Aims<\/jats:title>\n\t    <jats:p>Venlafaxine is used to treat depression worldwide. Previous reviews have demonstrated that venlafaxine lowers scores on depression rating scales, producing statistically significant results but the relevance to patients remains uncertain. Knowledge of the incidence of the adverse effects associated with venlafaxine has previously been based on the results of non-randomised studies. Our primary objective was to assess the risks of adverse events with venlafaxine in the treatment of adults with major depressive disorder in randomised trials.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2045796024000520_sec2b\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>We searched relevant databases and other sources from inception to 7 March 2024 for randomised clinical trials comparing venlafaxine versus placebo or no intervention in adults with major depressive disorder. Data were synthesised using meta-analysis and Trial Sequential Analysis. The primary outcomes were suicides or suicide attempts, serious adverse events and non-serious adverse events.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2045796024000520_sec3c\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>We included 28 trials randomising 6,253 participants to venlafaxine versus placebo. All results were at high risk of bias, and the certainty of the evidence was very low. All trials assessed outcomes at a maximum of 12 weeks after randomisation. Meta-analysis and Trial Sequential Analysis showed insufficient information to assess the effects of venlafaxine on the risks of suicides or suicide attempts. Meta-analysis showed evidence of harm of venlafaxine versus placebo on serious adverse events (risk ratio: 2.66; 95% confidence interval: 1.67\u20134.25; <jats:italic>p<\/jats:italic> &lt; 0.01; 22 trials), mainly due to a higher risk of sexual dysfunction and anorexia. Meta-analysis showed that venlafaxine also increased the risk of several non-serious adverse events: nausea, dry mouth, dizziness, sweating, somnolence, constipation, nervousness, insomnia, asthenia, tremor and decreased appetite.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2045796024000520_sec4d\">\n\t    <jats:title>Conclusions<\/jats:title>\n\t    <jats:p>Short-term results show that venlafaxine has uncertain effects on the risks of suicides but increases the risks of serious adverse events (especially sexual dysfunction and anorexia) and many non-serious adverse events. The long-term effects of venlafaxine for major depressive disorder are unknown. It is a particular cause for concern that there are no data on the long-term adverse effects of venlafaxine given that so many people use these drugs for several years.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/s2045796024000520","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T08:31:18Z","timestamp":1729672278000},"source":"Crossref","is-referenced-by-count":22,"title":["The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis"],"prefix":"10.1017","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-4694","authenticated-orcid":false,"given":"C. B.","family":"Kamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Faltermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1214-6974","authenticated-orcid":false,"given":"J.","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2956-2969","authenticated-orcid":false,"given":"M. P.","family":"Hengartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-4061","authenticated-orcid":false,"given":"I.","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"S2045796024000520_ref15","unstructured":"Eudract 2004-000562-13 (2016) A multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study of DVS-233 SR and venlafaxine ER in adult outpatients with major depressive disorder."},{"key":"S2045796024000520_ref72","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199108000-00002"},{"key":"S2045796024000520_ref81","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0430-4"},{"key":"S2045796024000520_ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01246-4"},{"key":"S2045796024000520_ref39","doi-asserted-by":"publisher","DOI":"10.1177\/00048674231218623"},{"key":"S2045796024000520_ref51","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32830263de"},{"key":"S2045796024000520_ref53","first-page":"637","article-title":"A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression","volume":"32","author":"Luthringer","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"S2045796024000520_ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2005.07.009"},{"key":"S2045796024000520_ref27","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000105"},{"key":"S2045796024000520_ref6","article-title":"Venlafaxine and serious withdrawal symptoms: Warning to drivers","volume":"7","author":"Campagne","year":"2005","journal-title":"Medscape General Medicine"},{"key":"S2045796024000520_ref55","article-title":"Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: Comparison of clinical study reports, trial registries, and publications","volume":"348","author":"Maund","year":"2014","journal-title":"The BMJ"},{"key":"S2045796024000520_ref77","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0105"},{"key":"S2045796024000520_ref64","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852918001207"},{"key":"S2045796024000520_ref83","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"key":"S2045796024000520_ref57","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"S2045796024000520_ref66","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0305"},{"key":"S2045796024000520_ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011890"},{"key":"S2045796024000520_ref86","doi-asserted-by":"publisher","DOI":"10.1159\/000457131"},{"key":"S2045796024000520_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199404000-00003"},{"key":"S2045796024000520_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011"},{"key":"S2045796024000520_ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01705-6"},{"key":"S2045796024000520_ref26","unstructured":"Higgins, J , Thomas, J , Chandler, J , Cumpston, M , Li, T , Page, M and Welch, V (2022) Handbook for Systematic Reviews of Interventions . https:www.training.cochrane.org\/handbook."},{"key":"S2045796024000520_ref54","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2007.13.s6-a.8"},{"key":"S2045796024000520_ref80","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"The BMJ"},{"key":"S2045796024000520_ref32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25"},{"key":"S2045796024000520_ref85","volume-title":"User Manual for Trial Sequential Analysis (TSA)","author":"Thorlund","year":"2017"},{"key":"S2045796024000520_ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02221-5"},{"key":"S2045796024000520_ref87","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051484"},{"key":"S2045796024000520_ref1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001027"},{"key":"S2045796024000520_ref74","article-title":"Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports","volume":"352","author":"Sharma","year":"2016","journal-title":"The BMJ"},{"key":"S2045796024000520_ref69","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000194645.70869.3b"},{"key":"S2045796024000520_ref91","unstructured":"World Health Organization (2023) Depressive disorder (depression). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression (accessed April 1 2023 )."},{"key":"S2045796024000520_ref94","unstructured":"Wyeth-Ayerst (1991c) Randomized, double-blind comparison of venlafaxine (WY-45, 030), imipramine, and placebo capsules in outpatients with major depression: Final report (protocol 600A-303-US\/303 Ext, unpublished data)."},{"key":"S2045796024000520_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn188"},{"key":"S2045796024000520_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2013.04.021"},{"key":"S2045796024000520_ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01789-0"},{"key":"S2045796024000520_ref42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300730"},{"key":"S2045796024000520_ref2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","year":"2013"},{"key":"S2045796024000520_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"S2045796024000520_ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002127"},{"key":"S2045796024000520_ref33","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12301"},{"key":"S2045796024000520_ref3","volume-title":"Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"S2045796024000520_ref58","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08443"},{"key":"S2045796024000520_ref43","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.7.617"},{"key":"S2045796024000520_ref24","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108089602"},{"key":"S2045796024000520_ref46","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199802000-00004"},{"key":"S2045796024000520_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.10.007"},{"key":"S2045796024000520_ref60","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S2045796024000520_ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111407"},{"key":"S2045796024000520_ref67","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(99)00067-1"},{"key":"S2045796024000520_ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2011.06.002"},{"key":"S2045796024000520_ref76","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01722-5"},{"key":"S2045796024000520_ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013"},{"key":"S2045796024000520_ref45","first-page":"141","article-title":"Venlafaxine in depressed outpatients","volume":"27","author":"Khan","year":"1991","journal-title":"Psychopharmacology Bulletin"},{"key":"S2045796024000520_ref50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"S2045796024000520_ref59","article-title":"Active placebos versus antidepressants for depression","volume":"2004","author":"Moncrieff","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S2045796024000520_ref48","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111424931"},{"key":"S2045796024000520_ref63","unstructured":"NHS East and North Hertfordshire Clinical Commissioning Group & NHS Herts Valleys Clinical Commissioning Group (2018) Guidelines on choice and selection of antidepressants for the management of depression. https:\/\/hertsvalleysccg.nhs.uk\/application\/files\/1615\/3633\/3654\/Guidelines_on_Choice_and_Selection_of_Antidepressants_for_the_Management_of_Depression_Final_Sept_2016.pdf (accessed 31 January 2022 )."},{"key":"S2045796024000520_ref70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2010.01599.x"},{"key":"S2045796024000520_ref92","unstructured":"Wyeth-Ayerst (1991a) A randomised, double-blind, parallel group comparison of venlafaxine and placebo capsules in inpatients with major depression and melancholia (protocol 600A-206, unpublished data)."},{"key":"S2045796024000520_ref96","unstructured":"Wyeth-Ayerst Research (1996) 600-B-367-EU: A randomized, double-blind, placebo-controlled, fixed dose study of the efficacy and safety of venlafaxine extended-release and paroxetine in depressed outpatients: Final report (unpublished data)."},{"key":"S2045796024000520_ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111600"},{"key":"S2045796024000520_ref73","first-page":"677","article-title":"Letters, numbers, symbols and words: How to communicate grades of evidence and recommendations","volume":"169","author":"Sch\u00fcnemann","year":"2003","journal-title":"Canadian Medical Association Journal"},{"key":"S2045796024000520_ref89","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-86"},{"key":"S2045796024000520_ref93","unstructured":"Wyeth-Ayerst (1991b) Randomized double-blind comparison of venlafaxine (WY-45, 030), imipramine, and placebo capsules in outpatients with major depression: Final report (protocol 600A-301-US\/301 Ext-US, unpublished data)."},{"key":"S2045796024000520_ref95","unstructured":"Wyeth-Ayerst (1992) Randomized, double-blind comparison of venlafaxine (WY-45, 030), trazodone, and placebo capsules in outpatients with major depression: Final report (protocol 600A-302-US, CA\/302 Ext, unpublished data)."},{"key":"S2045796024000520_ref75","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32831980f2"},{"key":"S2045796024000520_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00295-2"},{"key":"S2045796024000520_ref82","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0904"},{"key":"S2045796024000520_ref10","unstructured":"Covidence (2024) Covidence Systematic Review Software [ Online ]. Melbourne, Australia: Veritas Health Innovation. www.covidence.org (accessed 1 April 2024 )."},{"key":"S2045796024000520_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.08.027"},{"key":"S2045796024000520_ref79","volume-title":"Stata Statistical Software: Release 16","year":"2019"},{"key":"S2045796024000520_ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.10.357"},{"key":"S2045796024000520_ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"S2045796024000520_ref52","first-page":"143","article-title":"The Hamilton Rating Scale for Depression: A meta-analytic reliability generalization study","volume":"9","author":"L\u00f3pez-Pina","year":"2009","journal-title":"International Journal of Clinical and Health Psychology"},{"key":"S2045796024000520_ref35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-120"},{"key":"S2045796024000520_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.12.041"},{"key":"S2045796024000520_ref36","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp12X658304"},{"key":"S2045796024000520_ref44","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-90"},{"key":"S2045796024000520_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780060325"},{"key":"S2045796024000520_ref71","first-page":"104","article-title":"Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients","volume":"55","author":"Schweizer","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"S2045796024000520_ref84","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn179"},{"key":"S2045796024000520_ref20","first-page":"450","article-title":"Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia","volume":"56","author":"Guelfi","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"key":"S2045796024000520_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2009.06.006"},{"key":"S2045796024000520_ref9","unstructured":"Copenhagen Trial Unit \u2013 Centre for Clinical Intervention Research (2023) TSA - Trial Sequential Analysis 0.9.5.10 Beta [Computer program]. Copenhagen Trial Unit, Centre for Clinical Intervention Research 2023. http:\/\/www.ctu.dk\/tsa\/ (accessed 1 September 2020 )."},{"key":"S2045796024000520_ref25","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109106953"},{"key":"S2045796024000520_ref34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2019-111238"},{"key":"S2045796024000520_ref90","unstructured":"World Health Organization (2021) International Statistical Classification of Diseases and Related Health Problems (ICD). https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases (accessed 1 April 2024 )."},{"key":"S2045796024000520_ref68","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S159276"},{"key":"S2045796024000520_ref56","first-page":"169","article-title":"Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study","volume":"29","author":"Mendels","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"S2045796024000520_ref16","unstructured":"Eudract Number 2007-007025-51 (2010) A randomised, double-blind, parallel-group, placebo-controlled, and active-referenced study evaluating the efficacy and safety of three fixed-dose regimens of Lu AA34893 in the treatment of major depressive disorder."},{"key":"S2045796024000520_ref61","unstructured":"National Health Service (2018) Venlafaxine . https:\/\/www.nhs.uk\/medicines\/venlafaxine\/ (accessed 28 September 2021 )."},{"key":"S2045796024000520_ref31","unstructured":"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2015) ICH harmonised guideline: Integrated addendum to ICH E6(R1): Guideline for good clinical practice (ICH-GCP). Step 2 version. https:\/\/ichgcp.net\/da (accessed 1 September 2020 )."},{"key":"S2045796024000520_ref78","volume-title":"Venlafaxine","author":"Singh","year":"2021"},{"key":"S2045796024000520_ref17","unstructured":"European Medicines Agency (2008) Efexor . https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/efexor (accessed 1 April 2023 )."},{"key":"S2045796024000520_ref11","doi-asserted-by":"publisher","DOI":"10.3109\/10401239709147791"}],"container-title":["Epidemiology and Psychiatric Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2045796024000520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T08:31:30Z","timestamp":1729672290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2045796024000520\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":96,"alternative-id":["S2045796024000520"],"URL":"https:\/\/doi.org\/10.1017\/s2045796024000520","relation":{},"ISSN":["2045-7960","2045-7979"],"issn-type":[{"value":"2045-7960","type":"print"},{"value":"2045-7979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e51"}}